130 related articles for article (PubMed ID: 9693220)
1. Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of nitric oxide.
Gupta TK; Toruner M; Groszmann RJ
Digestion; 1998; 59(4):413-5. PubMed ID: 9693220
[No Abstract] [Full Text] [Related]
2. Hepatic stellate cells and intrahepatic modulation of portal pressure.
Mallat A
Digestion; 1998; 59(4):416-9. PubMed ID: 9693221
[No Abstract] [Full Text] [Related]
3. Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of endothelins.
Gerbes AL; Bilzer M; Gülberg V
Digestion; 1998; 59(4):410-2. PubMed ID: 9693219
[No Abstract] [Full Text] [Related]
4. Intrahepatic modulation of portal pressure and its role in portal hypertension.
Wheatley AM; Zhang X
Digestion; 1998; 59(4):424-8. PubMed ID: 9693223
[No Abstract] [Full Text] [Related]
5. Stellate cells and the "reversible component" of portal hypertension.
de Franchis R
Dig Liver Dis; 2000 Mar; 32(2):104-7. PubMed ID: 10975782
[No Abstract] [Full Text] [Related]
6. The role of vasoactive mediators in portal hypertension.
García-Pagán JC; Bosch J; Rodés J
Semin Gastrointest Dis; 1995 Jul; 6(3):140-7. PubMed ID: 7551971
[No Abstract] [Full Text] [Related]
7. Current concepts on the pathophysiology of portal hypertension.
Rodríguez-Vilarrupla A; Fernández M; Bosch J; García-Pagán JC
Ann Hepatol; 2007; 6(1):28-36. PubMed ID: 17297426
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of increased intrahepatic resistance in portal hypertension.
Shah V
J Clin Gastroenterol; 2007; 41 Suppl 3():S259-61. PubMed ID: 17975474
[TBL] [Abstract][Full Text] [Related]
9. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
[TBL] [Abstract][Full Text] [Related]
10. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
[TBL] [Abstract][Full Text] [Related]
11. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance.
Wiest R; Groszmann RJ
Semin Liver Dis; 1999; 19(4):411-26. PubMed ID: 10643626
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamics in the isolated cirrhotic liver.
Zipprich A
J Clin Gastroenterol; 2007; 41 Suppl 3():S254-8. PubMed ID: 17975473
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis.
Langer DA; Shah VH
J Hepatol; 2006 Jan; 44(1):209-16. PubMed ID: 16297493
[No Abstract] [Full Text] [Related]
15. Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.
Theodorakis NG; Wang YN; Korshunov VA; Maluccio MA; Skill NJ
World J Gastroenterol; 2015 Apr; 21(14):4126-35. PubMed ID: 25892862
[TBL] [Abstract][Full Text] [Related]
16. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
Theodorakis NG; Wang YN; Wu JM; Maluccio MA; Sitzmann JV; Skill NJ
Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G792-9. PubMed ID: 19628654
[TBL] [Abstract][Full Text] [Related]
17. Murine study of portal hypertension associated endothelin-1 hypo-response.
Theodorakis N; Maluccio M; Skill N
World J Gastroenterol; 2015 Apr; 21(16):4817-28. PubMed ID: 25944995
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
19. [The role of nitric oxide in the pathogenesis of portal hypertension].
Zhu J; Wang D; Leng X; Zhang Z; Wang F; Peng J; Du R
Zhonghua Wai Ke Za Zhi; 2000 Feb; 38(2):95-7. PubMed ID: 11831997
[TBL] [Abstract][Full Text] [Related]
20. [The role of nitric oxide in hyperdynamic circulation in portal hypertensive rats].
Wu Z; Zhou J; Chen Z; Zhou H; Jiao Z; Kuang Y; Yuan J; Wang Q; Zeng M
Zhonghua Wai Ke Za Zhi; 1998 Mar; 36(3):182-6. PubMed ID: 11825365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
